Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Acetazolamide (Diamox)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Acetazolamide (Diamox ®) (opens in a new tab)Original source URL: https://globalrph.com/dilution/acetazolamide/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/acetazolamide/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:45:24.346151+00:00
Source location
div.post-content
Packaged content SHA-256
3804496ce888e7d00a0d2c3e85eb4cd53b83a1f5a5669257a91666b260b69c91
Original response SHA-256
47b4660de5407297d37522391e1d84d47fba606efad03d687da759eea8df2ada
Source body SHA-256
761c8d7c408aeb78daee0034c0727eb2f00d6facff23bdcf59ba972a997a3a57

Acetazolamide (Diamox ®)

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

Admixture:
[250-500 mg] [50 ml] [15-30 min]

Recommended route:
IV-push (100-500 mg/min)

Stability / Miscellaneous

Stability data:

Stability Refrigerated: Reconstituted solutions retain their physical
and chemical properties for 3 days under refrigeration at 2° to 8°C (36°
to 46°F)
Stability Room Temp: Store at 20° to 25°C (68° to 77°F) excursions
permitted between 15° to 30°C (59° to 86°F)

Reconstituted solutions retain their physical and chemical properties
for 12 hours at room temperature 20° to 25°C (68° to 77°F).
Reconstituted Vial/Powder: Powder


Notes:
Contains no preservative. Discard unused portion.

(package insert): Store drug product at controlled room temperature 15°-30°C (59°-86°F). Reconstituted solution should be stored in refrigerator at 2°- 8°C (36° - 46°F). Use within 12 hours of reconstitution. Contains no preservative. Discard unused portion.

(Alternative sources):
Injection: Store vial for injection (prior to reconstitution) at controlled room temperature. Reconstitute with at least 5 mL sterile water to provide a solution containing not more than 100 mg/mL. Reconstituted solution may be refrigerated (2°C to 8°C) for 1 week, however, use within 12 hours is recommended. Further dilute in D5W or NS for I.V. infusion. Stability of IVPB solution is 5 days at room temperature (25°C) and 44 days at refrigeration (5°C).

Dosing adjustment in renal impairment:
Clcr 10-50 mL/minute: Administer every 12 hours
Clcr<10 mL/minute: Avoid use (ineffective)
Hemodialysis: Moderately dialyzable (20% to 50%)
Peritoneal dialysis: Supplemental dose is not necessary

Separate renal reference: Open Renal Dosing Master (opens in a new tab)

DOSAGE AND ADMINISTRATION

Preparation and Storage of Parenteral Solution
Each 500 mg vial containing sterile acetazolamide sodium should be reconstituted with at least 5 mL of Sterile Water for Injection prior to use. Reconstituted solutions retain their physical and chemical properties for 3 days under refrigeration at 2° - 8° C (36° - 46° F), or 12 hours at room temperature 15° - 30° C (59° - 86° F). Contains no preservative.

The direct intravenous route of administration is preferred. Intramuscular administration is not recommended.

Glaucoma
Acetazolamide should be used as an adjunct to the usual therapy. The dosage employed in the treatment of chronic simple (open-angle) glaucoma ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided doses for amounts over 250 mg. It has usually been found that a dosage in excess of 1 g per 24 hours does not produce an increased effect.

Epilepsy
It is not clearly known whether the beneficial effects observed in epilepsy are due to direct inhibition of carbonic anhydrase in the central nervous system or whether they are due to the slight degree of acidosis produced by the divided dosage. The best results to date have been seen in petit mal in children. Good results, however, have been seen in patients, both children and adult, in other types of seizures such as grand mal, mixed seizure patterns, myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per kg in divided doses. Although some patients respond to a low dose, the optimum range appears to be from 375 to 1000 mg daily. However, some investigators feel that daily doses in excess of 1 g do not produce any better results than a 1 g dose. When acetazolamide is given in combination with other anticonvulsants, it is suggested that the starting dose should be 250 mg once daily in addition to the existing medications. This can be increased to levels as indicated above. The change from other medications to acetazolamide should be gradual and in accordance with usual practice in epilepsy therapy.

Congestive Heart Failure
For diuresis in congestive heart failure, the starting dose is usually 250 to 375 mg once daily in the morning (5 mg per kg). If, after an initial response, the patient fails to continue to lose edema fluid, do not increase the dose but allow for kidney recovery by skipping medication for a day. Acetazolamide yields best diuretic results when given on alternate days, or for two days alternating with a day of rest. Failures in therapy may be due to overdosage or too frequent dosage. The use of acetazolamide does not eliminate the need for other therapy such as digitalis, bed rest, and salt restriction.

Drug-Induced Edema
Recommended dosage is 250 to 375 mg of acetazolamide once a day for one or two days, alternating with a day of rest.

Note: The dosage recommendations for glaucoma and epilepsy differ considerably from those for congestive heart failure, since the first two conditions are not dependent upon carbonic anhydrase inhibition in the kidney which requires intermittent dosage if it is to recover from inhibitory effect of the therapeutic agent.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
adjustment_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      acetazolamide-diamox
      Source IDH51-14076ABF2B34DEA766C59686
      Generic name
      Acetazolamide (Diamox)
      Source IDH51-98FF64112B0446DAD0C9EE9E
      Class
      Endocrine and metabolic
      Source IDH51-0AC6EB512BA35DEEC5B9982E
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-7E77182AA250D39B9392BF99
      Primary uses
      1. Acute endocrine, metabolic, obstetric, or hemostatic indications that match the named hormone or metabolic agent.
        Source IDH51-3F0ED7102241CB289977858F
      Mechanism
      Inhibits carbonic anhydrase and reduces proximal tubular bicarbonate reabsorption.
      Source IDH51-BB39F4CAE5D9946B6BC432C6
      Mechanism level
      drug_specific
      Source IDH51-7CA238B6B24C465205B60E30
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-F55C43615C6E8A359F6834B7
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-4F0CAE29F9EE931B0E6247CF
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-1DC013DE5684EBB93FC9FBC7
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-9C8B4934B98802D61C32448D
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-7DDC4F3439FF5FDAE9B1FCA2
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-6AE9E026FD91E5E3D3EC92DE
      Legacy title
      Acetazolamide (Diamox)
      Source IDH51-2D4E9F01BA349587F5B9F0CC
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-EC1CCD764FD62E9DC04F39DB
      Search text
      Acetazolamide (Diamox) Endocrine and metabolic Legacy GlobalRPh directory entry Acute endocrine, metabolic, obstetric, or hemostatic indications that match the named hormone or metabolic agent. Inhibits carbonic anhydrase and reduces proximal tubular bicarbonate reabsorption. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-3815F01C8A04194BED6E2228
      Official access mode
      none
      Source IDH51-A147026C57FCE5AD523C1C3D
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-077B6504EDB6E2E29F4FC29F

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      adjustment_required
      Source IDH51-7872C00F429FC99CE51B4D58
      Summary
      Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-7646A49E1191E5042000A071
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-BBFFA1C8C9F9245BBD00114D

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-1E5EE21707AE7AA8535C8E9D

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-721DCCDFF2F853B9AEA65C8E
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      acetazolamide-diamox
      Source IDH51-D5DC62353E6F080A31082ADB
      Legacy title
      Acetazolamide (Diamox)
      Source IDH51-B262CFC7B43458A3A36B0CBD
      Generic name
      Acetazolamide (Diamox)
      Source IDH51-5765D52D9C30E48D93AB2674
      Class
      Endocrine and metabolic
      Source IDH51-BE865F1CD4D4C32235B67CFD
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-E1996D730833E793EBC0865C
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-FE147A357A5D77050BF35A51
      Populations
      1. Population not yet normalized
        Source IDH51-9115DAD4A2D9B76420A9ABD8
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-5EC341C3F04260CF4912FC27
      High alert
      false
      Source IDH51-0842F85EE429577BCB26BB25
      Hazardous
      false
      Source IDH51-6941B08BFBF2DAFF7C0B4DE8
      Status
      Legacy migration
      Source IDH51-27328BD07687479754DA4311
      Version added
      Legacy
      Source IDH51-0C8BCE2BE7F3E80F55767DA4
      Sources
      LabelUrlKind
      Source IDH51-D0800AD1FC6F461AD4D66B5B
      GlobalRPh legacy IV dilution monograph
      Source IDH51-8EFBD1E36D29850405F00371
      legacy:auto
      Source IDH51-9D334929B70AB5F9DD1653F6
      Legacy
      Source IDH51-DC3C384F7FB6A7376D033752
      Clinical release verification
      Audit version
      3.4
      Source IDH51-0FD3DD74DA578E3A0B1F769A
      Audited on
      2026-08-30
      Source IDH51-A82E5856BF832C44EF259224
      Level
      red
      Source IDH51-FAA35064E2A977CE5CB342DD
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-D2A324A10448FDCA0BB7CAAF
      Exact current label candidate
      false
      Source IDH51-766DB33D810FE2E7DD3F43D8
      Reference url count
      0
      Source IDH51-B17A8E671F88AF49A98E2EB1
      Broken reference count
      0
      Source IDH51-F82C863CA3A8F3E591CB70A2
      Point of use confirmation required
      true
      Source IDH51-00FCD6378FDB467BF6C47AE5
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-A89BAC57469A65147A34CBFF

      Dosing source fields

      Id
      acetazolamide-diamox
      Source IDH51-D84A32EDB17DA33F6FA28FFE
      Generic name
      Acetazolamide (Diamox)
      Source IDH51-6BD6322734FF7B66E7DB9325
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-7A49095261E3C6F090BD7FB8
      Package insert
      Query name
      Acetazolamide
      Source IDH51-BEB3F40BBAA0DB61C4071F9C
      Product and route must match
      true
      Source IDH51-E15B2777AF116FE09107F9AE
      Live current label enabled
      false
      Source IDH51-800E5838D67C65AC50BC1FC1
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-6674293D2EBC684E514ADBC6
      Direct official label access enabled
      true
      Source IDH51-11E9B8F9D86482BCFD146A1E
      Outbound server request required
      false
      Source IDH51-46386106716C01BA4395D161
      Local summary status
      not_bundled
      Source IDH51-0CAAFFD8EF27E10EE7A1D4B2
      Clinical review
      Locally normalized
      false
      Source IDH51-A7E118D33B86976DA1F2844C
      Reviewed
      2026-08-29
      Source IDH51-B5E90AC436F060D7EE888DAB
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-339C46931616FAFC11467F10
      Clinical release verification
      Audit version
      3.4
      Source IDH51-9DF14017BFA6F5F905630C1C
      Audited on
      2026-08-30
      Source IDH51-85A205BA355052E4D73F4986
      Level
      red
      Source IDH51-ECA258BE949BF5290782D523
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-E1F2F69B5A7BFCA0DDFE56E3
      Exact current label candidate
      false
      Source IDH51-65F00B4C60D7CC2815E7FAB5
      Reference url count
      0
      Source IDH51-1816A8FCA4147B5771835745
      Broken reference count
      0
      Source IDH51-F10FFD672046DB8DD7CBAC0D
      Point of use confirmation required
      true
      Source IDH51-39F4B094A05488CA9FC9F748
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-CE8C8F84D34BB7D93B5E7378
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      acetazolamide-diamox
      Source IDH51-F67D8B0FD765A32B708E05C1
      Name
      Acetazolamide (Diamox)
      Source IDH51-9BE4A0DDC37C3195FD6942D8
      Therapeutic class
      Endocrine and metabolic
      Source IDH51-CB34DC97A1AB09CF9F062942
      Review version
      3.1
      Source IDH51-DB874146686F6B07AA16E7B2
      Review date
      2026-08-30
      Source IDH51-30C630794322145C2EBC4C12
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-1D8B36E9B39749CC4AAC61EA
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-4391DD9C2FBF05FAFC713873
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-EC76343B096FB3C9AE3F557D
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E830C8D4A6C8E8CD0D169633
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B769B61DDBFEF55DF9C0DED7
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-8B245A746CE3BBD2D4B36F88
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E0C17EC0FAE7335595ADA340
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-265CD3240C271707029D55AA
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-28DC7BD303F5CD685ED947AE
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-25CB07D85022D06308FE11FE
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C5A99EB34CC7A18E17572B69
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-14CA707C05BF5D613D1DBC1C
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-22C8A17D55DD54F9016A3B60
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-F26741708D0C00983C112B03
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-C2E6242A418834539245355A
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-76EEDA7349455B88D97E02E6
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-A08658DD42C0C76E2454DD92
      Adult dosing range
      Primary
      not_found
      Source IDH51-2AD7B99234951793062B3DC7
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-2CEC3315BC40CB9597FE6BCB
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-E3C7E18D22311114912BDA2A
      Infusion time
      Primary
      not_found
      Source IDH51-1AD326A90076B04CE92650B6
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-5A8FE4246F46DE3DF6339048
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-AC63DBF3AB5D7795F3DEF65B
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-7A0874BDC17ABA36F1C78AEA
      Guide generation allowed
      false
      Source IDH51-3A555EF60BCDB01447DEE2BB
      Pediatric
      Applicability
      not_established
      Source IDH51-DA77E86A4056E6B59DD76C3E
      Guide generation allowed
      false
      Source IDH51-4B409C9409806C3980D85B5C
      Neonatal
      Applicability
      not_established
      Source IDH51-57CAF627899D9E61C404F083
      Guide generation allowed
      false
      Source IDH51-221DA0D7C125FBC8F6A2A241
      Route presence
      Structured dilution
      false
      Source IDH51-5EB28B386DB1DD0098D1B14B
      Iv push
      false
      Source IDH51-250A95187F996C7D7BB691F2
      Continuous infusion
      false
      Source IDH51-8AFDABF8EE5693C3674BA5C6
      Pediatric source
      false
      Source IDH51-EEA21C6627A13FC5951DB9D2
      Neonatal source
      false
      Source IDH51-67B4B0071AE1EE79D811B903
      Legacy reference
      Status
      not_available
      Source IDH51-26590BC2CA6B951DBA1BB63E
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-E13DA5D5B1B4A63F30953110
      Source files
      1. catalog.json
        Source IDH51-3D39FC9F7E7F720CA60F203F
      2. dosing.json
        Source IDH51-2E72E2B2F9D35DC5CA1315D5
      3. legacy-map.json
        Source IDH51-830DBC485997A0F962D7DD67
      4. review-queue.json
        Source IDH51-2D7EA947A2E210BF5A792D59
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-9C69E4D21C8EB6E4EEAA6AAE
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-D5DC62353E6F080A31082ADBcatalog.json
      /records/2/id
      Historical; current review incomplete
      H51-B262CFC7B43458A3A36B0CBDcatalog.json
      /records/2/legacy_title
      Historical; current review incomplete
      H51-5765D52D9C30E48D93AB2674catalog.json
      /records/2/generic_name
      Historical; current review incomplete
      H51-BE865F1CD4D4C32235B67CFDcatalog.json
      /records/2/class
      Historical; current review incomplete
      H51-E1996D730833E793EBC0865Ccatalog.json
      /records/2/subclass
      Historical; current review incomplete
      H51-FE147A357A5D77050BF35A51catalog.json
      /records/2/summary
      Historical; current review incomplete
      H51-1E5EE21707AE7AA8535C8E9Dcatalog.json
      /records/2/warnings/0
      Historical; current review incomplete
      H51-721DCCDFF2F853B9AEA65C8Ecatalog.json
      /records/2/stability_notes/0
      Historical; current review incomplete
      H51-9115DAD4A2D9B76420A9ABD8catalog.json
      /records/2/populations/0
      Historical; current review incomplete
      H51-5EC341C3F04260CF4912FC27catalog.json
      /records/2/evidence_tier
      Historical; current review incomplete
      H51-0842F85EE429577BCB26BB25catalog.json
      /records/2/high_alert
      Historical; current review incomplete
      H51-6941B08BFBF2DAFF7C0B4DE8catalog.json
      /records/2/hazardous
      Historical; current review incomplete
      H51-27328BD07687479754DA4311catalog.json
      /records/2/status
      Historical; current review incomplete
      H51-35ED25DED9ABAB07DACDD3A5catalog.json
      /records/2/reviewed
      Historical; current review incomplete
      H51-0C8BCE2BE7F3E80F55767DA4catalog.json
      /records/2/version_added
      Historical; current review incomplete
      H51-D0800AD1FC6F461AD4D66B5Bcatalog.json
      /records/2/sources/0
      Historical; current review incomplete
      H51-8EFBD1E36D29850405F00371catalog.json
      /records/2/sources/0/label
      Historical; current review incomplete
      H51-9D334929B70AB5F9DD1653F6catalog.json
      /records/2/sources/0/url
      Historical; current review incomplete
      H51-DC3C384F7FB6A7376D033752catalog.json
      /records/2/sources/0/kind
      Historical; current review incomplete
      H51-0FD3DD74DA578E3A0B1F769Acatalog.json
      /records/2/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-A82E5856BF832C44EF259224catalog.json
      /records/2/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-FAA35064E2A977CE5CB342DDcatalog.json
      /records/2/clinical_release_verification/level
      Historical; current review incomplete
      H51-D2A324A10448FDCA0BB7CAAFcatalog.json
      /records/2/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-766DB33D810FE2E7DD3F43D8catalog.json
      /records/2/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-48CB3F05CBC265EC9BFC59E8catalog.json
      /records/2/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-4655997682D64E03DEC8886Bcatalog.json
      /records/2/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-89DCD59E2107196E8C647845catalog.json
      /records/2/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-B17A8E671F88AF49A98E2EB1catalog.json
      /records/2/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-F82C863CA3A8F3E591CB70A2catalog.json
      /records/2/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-00FCD6378FDB467BF6C47AE5catalog.json
      /records/2/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-A89BAC57469A65147A34CBFFcatalog.json
      /records/2/clinical_release_verification/note
      Historical; current review incomplete
      H51-6C921C0A0CD8602B5A84D680catalog.json
      /records/2/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-D84A32EDB17DA33F6FA28FFEdosing.json
      /records/2/id
      Historical; current review incomplete
      H51-6BD6322734FF7B66E7DB9325dosing.json
      /records/2/generic_name
      Historical; current review incomplete
      H51-7A49095261E3C6F090BD7FB8dosing.json
      /records/2/coverage_status
      Historical; current review incomplete
      H51-BEB3F40BBAA0DB61C4071F9Cdosing.json
      /records/2/package_insert/query_name
      Historical; current review incomplete
      H51-07CF6FC3A24B7200A2C21247dosing.json
      /records/2/package_insert/preferred_setid
      Historical; current review incomplete
      H51-E15B2777AF116FE09107F9AEdosing.json
      /records/2/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-800E5838D67C65AC50BC1FC1dosing.json
      /records/2/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-6674293D2EBC684E514ADBC6dosing.json
      /records/2/package_insert/source_priority
      Historical; current review incomplete
      H51-11E9B8F9D86482BCFD146A1Edosing.json
      /records/2/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-46386106716C01BA4395D161dosing.json
      /records/2/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-0CAAFFD8EF27E10EE7A1D4B2dosing.json
      /records/2/package_insert/local_summary_status
      Historical; current review incomplete
      H51-7872C00F429FC99CE51B4D58dosing.json
      /records/2/renal/classification
      Historical; current review incomplete
      H51-7646A49E1191E5042000A071dosing.json
      /records/2/renal/summary
      Historical; current review incomplete
      H51-BBFFA1C8C9F9245BBD00114Ddosing.json
      /records/2/renal/method_note
      Historical; current review incomplete
      H51-A7E118D33B86976DA1F2844Cdosing.json
      /records/2/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-B5E90AC436F060D7EE888DABdosing.json
      /records/2/clinical_review/reviewed
      Historical; current review incomplete
      H51-339C46931616FAFC11467F10dosing.json
      /records/2/clinical_review/status
      Historical; current review incomplete
      H51-9DF14017BFA6F5F905630C1Cdosing.json
      /records/2/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-85A205BA355052E4D73F4986dosing.json
      /records/2/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-ECA258BE949BF5290782D523dosing.json
      /records/2/clinical_release_verification/level
      Historical; current review incomplete
      H51-E1F2F69B5A7BFCA0DDFE56E3dosing.json
      /records/2/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-65F00B4C60D7CC2815E7FAB5dosing.json
      /records/2/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-241716A69114E46DEFED9ECFdosing.json
      /records/2/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-533420AD8FEE9D7E6939849Adosing.json
      /records/2/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-42F4B99983D886207616E700dosing.json
      /records/2/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-1816A8FCA4147B5771835745dosing.json
      /records/2/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-F10FFD672046DB8DD7CBAC0Ddosing.json
      /records/2/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-39F4B094A05488CA9FC9F748dosing.json
      /records/2/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-CE8C8F84D34BB7D93B5E7378dosing.json
      /records/2/clinical_release_verification/note
      Historical; current review incomplete
      H51-4FDFAD63596951C4664893EBdosing.json
      /records/2/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-14076ABF2B34DEA766C59686first-look-v5.1.json
      /records/2/id
      Historical; current review incomplete
      H51-98FF64112B0446DAD0C9EE9Efirst-look-v5.1.json
      /records/2/generic_name
      Historical; current review incomplete
      H51-0AC6EB512BA35DEEC5B9982Efirst-look-v5.1.json
      /records/2/class
      Historical; current review incomplete
      H51-7E77182AA250D39B9392BF99first-look-v5.1.json
      /records/2/subclass
      Historical; current review incomplete
      H51-3F0ED7102241CB289977858Ffirst-look-v5.1.json
      /records/2/primary_uses/0
      Historical; current review incomplete
      H51-BB39F4CAE5D9946B6BC432C6first-look-v5.1.json
      /records/2/mechanism
      Historical; current review incomplete
      H51-7CA238B6B24C465205B60E30first-look-v5.1.json
      /records/2/mechanism_level
      Historical; current review incomplete
      H51-F55C43615C6E8A359F6834B7first-look-v5.1.json
      /records/2/basic_dosing_orientation
      Historical; current review incomplete
      H51-4F0CAE29F9EE931B0E6247CFfirst-look-v5.1.json
      /records/2/administration_orientation
      Historical; current review incomplete
      H51-1DC013DE5684EBB93FC9FBC7first-look-v5.1.json
      /records/2/renal_and_population_orientation
      Historical; current review incomplete
      H51-9C8B4934B98802D61C32448Dfirst-look-v5.1.json
      /records/2/key_safety_orientation/0
      Historical; current review incomplete
      H51-7DDC4F3439FF5FDAE9B1FCA2first-look-v5.1.json
      /records/2/coverage_path
      Historical; current review incomplete
      H51-6AE9E026FD91E5E3D3EC92DEfirst-look-v5.1.json
      /records/2/coverage_path_label
      Historical; current review incomplete
      H51-9678006E39381FBF3DBB6AD7first-look-v5.1.json
      /records/2/official_label_url
      Historical; current review incomplete
      H51-2D4E9F01BA349587F5B9F0CCfirst-look-v5.1.json
      /records/2/legacy_title
      Historical; current review incomplete
      H51-EC1CCD764FD62E9DC04F39DBfirst-look-v5.1.json
      /records/2/review_note
      Historical; current review incomplete
      H51-3815F01C8A04194BED6E2228first-look-v5.1.json
      /records/2/search_text
      Historical; current review incomplete
      H51-04B6A3B0423132388798C78Bfirst-look-v5.1.json
      /records/2/official_search_url
      Historical; current review incomplete
      H51-A147026C57FCE5AD523C1C3Dfirst-look-v5.1.json
      /records/2/official_access_mode
      Historical; current review incomplete
      H51-7566604D9318BB84FE43E4CFfirst-look-v5.1.json
      /records/2/official_access_url
      Historical; current review incomplete
      H51-93C885EFEFD6C90E74D35A8Cfirst-look-v5.1.json
      /records/2/official_search_query
      Historical; current review incomplete
      H51-077B6504EDB6E2E29F4FC29Ffirst-look-v5.1.json
      /records/2/official_access_reason
      Historical; current review incomplete
      H51-F67D8B0FD765A32B708E05C1preparation-assessments-v3.8.json
      /2/id
      Historical; current review incomplete
      H51-9BE4A0DDC37C3195FD6942D8preparation-assessments-v3.8.json
      /2/name
      Historical; current review incomplete
      H51-7F183B5D570DDA0B432BE3B7preparation-assessments-v3.8.json
      /2/brands
      Historical; current review incomplete
      H51-CB34DC97A1AB09CF9F062942preparation-assessments-v3.8.json
      /2/therapeutic_class
      Historical; current review incomplete
      H51-DB874146686F6B07AA16E7B2preparation-assessments-v3.8.json
      /2/review_version
      Historical; current review incomplete
      H51-30C630794322145C2EBC4C12preparation-assessments-v3.8.json
      /2/review_date
      Historical; current review incomplete
      H51-1D8B36E9B39749CC4AAC61EApreparation-assessments-v3.8.json
      /2/release_status
      Historical; current review incomplete
      H51-4391DD9C2FBF05FAFC713873preparation-assessments-v3.8.json
      /2/market_status/status
      Historical; current review incomplete
      H51-EC76343B096FB3C9AE3F557Dpreparation-assessments-v3.8.json
      /2/market_status/basis
      Historical; current review incomplete
      H51-E830C8D4A6C8E8CD0D169633preparation-assessments-v3.8.json
      /2/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-B769B61DDBFEF55DF9C0DED7preparation-assessments-v3.8.json
      /2/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-8B245A746CE3BBD2D4B36F88preparation-assessments-v3.8.json
      /2/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-E0C17EC0FAE7335595ADA340preparation-assessments-v3.8.json
      /2/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-265CD3240C271707029D55AApreparation-assessments-v3.8.json
      /2/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-28DC7BD303F5CD685ED947AEpreparation-assessments-v3.8.json
      /2/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-25CB07D85022D06308FE11FEpreparation-assessments-v3.8.json
      /2/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-C5A99EB34CC7A18E17572B69preparation-assessments-v3.8.json
      /2/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-14CA707C05BF5D613D1DBC1Cpreparation-assessments-v3.8.json
      /2/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-FF7347BA0362050E4B9D7531preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-011C7C42A419CC2ACDB6DE60preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-DC9D13EBE04E0D9D2AA27335preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-6800FC02F795B6152CA4E0A5preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-22C8A17D55DD54F9016A3B60preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-EB2FD3D2FFCB699478AF4418preparation-assessments-v3.8.json
      /2/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-F26741708D0C00983C112B03preparation-assessments-v3.8.json
      /2/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-C2E6242A418834539245355Apreparation-assessments-v3.8.json
      /2/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-76EEDA7349455B88D97E02E6preparation-assessments-v3.8.json
      /2/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-A08658DD42C0C76E2454DD92preparation-assessments-v3.8.json
      /2/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-2AD7B99234951793062B3DC7preparation-assessments-v3.8.json
      /2/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-2CEC3315BC40CB9597FE6BCBpreparation-assessments-v3.8.json
      /2/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-E3C7E18D22311114912BDA2Apreparation-assessments-v3.8.json
      /2/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-1AD326A90076B04CE92650B6preparation-assessments-v3.8.json
      /2/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-5A8FE4246F46DE3DF6339048preparation-assessments-v3.8.json
      /2/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-AC63DBF3AB5D7795F3DEF65Bpreparation-assessments-v3.8.json
      /2/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-7A0874BDC17ABA36F1C78AEApreparation-assessments-v3.8.json
      /2/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-3A555EF60BCDB01447DEE2BBpreparation-assessments-v3.8.json
      /2/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-DA77E86A4056E6B59DD76C3Epreparation-assessments-v3.8.json
      /2/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-4B409C9409806C3980D85B5Cpreparation-assessments-v3.8.json
      /2/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-57CAF627899D9E61C404F083preparation-assessments-v3.8.json
      /2/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-221DA0D7C125FBC8F6A2A241preparation-assessments-v3.8.json
      /2/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-5EB28B386DB1DD0098D1B14Bpreparation-assessments-v3.8.json
      /2/route_presence/structured_dilution
      Historical; current review incomplete
      H51-250A95187F996C7D7BB691F2preparation-assessments-v3.8.json
      /2/route_presence/iv_push
      Historical; current review incomplete
      H51-8AFDABF8EE5693C3674BA5C6preparation-assessments-v3.8.json
      /2/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-EEA21C6627A13FC5951DB9D2preparation-assessments-v3.8.json
      /2/route_presence/pediatric_source
      Historical; current review incomplete
      H51-67B4B0071AE1EE79D811B903preparation-assessments-v3.8.json
      /2/route_presence/neonatal_source
      Historical; current review incomplete
      H51-26590BC2CA6B951DBA1BB63Epreparation-assessments-v3.8.json
      /2/legacy_reference/status
      Historical; current review incomplete
      H51-E13DA5D5B1B4A63F30953110preparation-assessments-v3.8.json
      /2/label_resolution/status
      Historical; current review incomplete
      H51-3D39FC9F7E7F720CA60F203Fpreparation-assessments-v3.8.json
      /2/source_files/0
      Historical; current review incomplete
      H51-2E72E2B2F9D35DC5CA1315D5preparation-assessments-v3.8.json
      /2/source_files/1
      Historical; current review incomplete
      H51-830DBC485997A0F962D7DD67preparation-assessments-v3.8.json
      /2/source_files/2
      Historical; current review incomplete
      H51-2D7EA947A2E210BF5A792D59preparation-assessments-v3.8.json
      /2/source_files/3
      Historical; current review incomplete
      H51-9C69E4D21C8EB6E4EEAA6AAEpreparation-assessments-v3.8.json
      /2/clinical_release_note
      Historical; current review incomplete